Immuron

Analyst Reports

Corporate Governance

Corporate Directory

Corporate

Capital Structure & Register

Annual Reports

Investor Presentations

NASDAQ

Investors

Company Media

Announcements

The Digest

Why Immuron?

Home

Plus Jakarta Sans

Click here to read full article

Tim Boreham highlights increasing attention from major pharmaceutical players as Immuron approaches key clinical milestones, particularly in NASH, where news of promising trial outcomes has already prompted “a number of letters of congratulations” from potential suitors. Despite historical leadership churn, CEO Dr Kanellos has brought stability to the company, helping it refocus and build momentum across its pipeline, including the commercial traction of Travelan and progress toward late‑stage studies.

Stockhead: Big Pharma is watching as Immuron edges towards trial results